📰 Markl Baum News
Page 4 - Markl Baum News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Markl Baum. Real-time updates on events, politics, business and more.
March 28, 2023
LOS ANGELES, March 28, 2023 /PRNewswire/ -- B. Riley Financial, Inc. , a diversified financial services platform, today announced that certain of its affiliates led the financing to support Harrow... | March 28, 2023
March 28, 2023
/PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley"), a diversified financial services platform, today announced that certain of its affiliates...
March 27, 2023
Operator: Good afternoon. And welcome to Harrows Q4 2022 Earnings Conference Call. My name is MJ, and I will be your operator for todays call.
December 14, 2022
Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food and...
October 6, 2022
NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC,...
September 28, 2022
IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly
September 28, 2022
/PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative...
September 27, 2022
IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years
September 27, 2022
27.09.2022 - Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local ... Seite 1
August 11, 2022
NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial...